Etoricoxib is safe and effective in preventing heterotopic ossification after primary total hip arthroplasty

Table 2 Follow-up data: all subjects with etoricoxib for PAO prophylaxis

Follow-up etoricoxib	Preop	Adherence to therapy (10 days)	Undesirable side effects	Early termination of therapy
Included	194
Clinical examination at discharge	194	190 (97.9%)	14 (C) (7.4%)	4 (D) (2.1%)

(C) Five patients reported gastric complaints that disappeared under symptomatic therapy with a proton pump inhibitor. Two patients had slightly increased blood pressure (not in need of therapy). Two patients reported cardiac arrhythmia that could not be detected with an electrocardiogram. One patient developed increased kidney retention values which returned to normal after stopping the drug (etoricoxib). Three patients reported fatigue. One patient showed a skin reaction with itching and rash that disappeared after weaning and local as well as oral administration of an antihistamine. (D) The administration of etoricoxib was early terminated in the two patients reporting cardiac arrhythmia, in the patient with increased kidney retention values, and the patient with skin reaction

ISSN: 1749-799X